

Colin Edward Murdoch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526215/publications.pdf>

Version: 2024-02-01

34
papers

1,947
citations

304368

22
h-index

395343

33
g-index

36
all docs

36
docs citations

36
times ranked

3735
citing authors

#	ARTICLE	IF	CITATIONS
1	Antioxidants in Pregnancy: Do We Really Need More Trials?. <i>Antioxidants</i> , 2022, 11, 812.	2.2	5
2	Endothelial NADPH oxidase 4 protects against angiotensin II-induced cardiac fibrosis and inflammation. <i>ESC Heart Failure</i> , 2021, 8, 1427-1437.	1.4	12
3	Computer-based virtual laboratory simulations: LabHEART cardiac physiology practical. <i>American Journal of Physiology - Advances in Physiology Education</i> , 2021, 45, 856-868.	0.8	0
4	Antioxidant synthetic peptides counteracting hyperglycaemia induced endothelial cell dysfunction. <i>International Journal of Cardiology</i> , 2020, 308, 82-83.	0.8	0
5	Endothelial cell-specific redox gene modulation inhibits angiogenesis but promotes B16F0 tumor growth in mice. <i>FASEB Journal</i> , 2019, 33, 14147-14158.	0.2	9
6	Cysteine Glutathionylation Acts as a Redox Switch in Endothelial Cells. <i>Antioxidants</i> , 2019, 8, 315.	2.2	33
7	IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages. <i>PLoS ONE</i> , 2019, 14, e0210827.	1.1	17
8	Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor. <i>Cell Death and Disease</i> , 2018, 9, 613.	2.7	65
9	Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 428.	1.6	37
10	Heterodimerisation between VEGFR-1 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity. <i>Vascular Pharmacology</i> , 2017, 88, 11-20.	1.0	9
11	Redox regulation of ischemic limb neovascularization – What we have learned from animal studies. <i>Redox Biology</i> , 2017, 12, 1011-1019.	3.9	34
12	Distinct Regulatory Effects of Myeloid Cell and Endothelial Cell NADPH Oxidase 2 on Blood Pressure. <i>Circulation</i> , 2017, 135, 2163-2177.	1.6	49
13	Vascular endothelial growth factor signaling requires glycine to promote angiogenesis. <i>Scientific Reports</i> , 2017, 7, 14749.	1.6	34
14	The Impact of Environmental Factors in Influencing Epigenetics Related to Oxidative States in the Cardiovascular System. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	1.9	27
15	Endothelial Cell Redox Regulation of Ischemic Angiogenesis. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 458-464.	0.8	14
16	Glutathione adducts induced by ischemia and deletion of glutaredoxin-1 stabilize HIF-1 α and improve limb revascularization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6011-6016.	3.3	76
17	Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 98, 11-17.	0.9	37
18	Stem Cell Therapies for Ischemic Cardiovascular Diseases. <i>Recent Patents on Regenerative Medicine</i> , 2015, 4, 149-167.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions. <i>Chemistry and Biology</i> , 2015, 22, 1347-1361.	6.2	39
20	Influence of Egr-1 in Cardiac Tissue-Derived Mesenchymal Stem Cells in Response to Glucose Variations. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	13
21	Glutaredoxin-1 Up-regulation Induces Soluble Vascular Endothelial Growth Factor Receptor 1, Attenuating Post-ischemia Limb Revascularization. <i>Journal of Biological Chemistry</i> , 2014, 289, 8633-8644.	1.6	56
22	Endothelial NADPH Oxidase-2 Promotes Interstitial Cardiac Fibrosis and Diastolic Dysfunction Through Proinflammatory Effects and Endothelial-Mesenchymal Transition. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2734-2741.	1.2	154
23	Regulation of neovascularization by S-glutathionylation via the Wnt5a/sFlt-1 pathway. <i>Biochemical Society Transactions</i> , 2014, 42, 1665-1670.	1.6	16
24	Gene Network and Proteomic Analyses of Cardiac Responses to Pathological and Physiological Stress. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 588-597.	5.1	21
25	Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. <i>Basic Research in Cardiology</i> , 2011, 106, 527-538.	2.5	137
26	Endothelial Nox4 NADPH Oxidase Enhances Vasodilatation and Reduces Blood Pressure In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1368-1376.	1.1	278
27	Constitutive glycogen synthase kinase-3 β activity protects against chronic β -adrenergic remodelling of the heart. <i>Cardiovascular Research</i> , 2010, 87, 494-503.	1.8	27
28	Defective peroxisomal proliferator-activated receptor γ activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. <i>European Journal of Heart Failure</i> , 2009, 11, 533-541.	2.9	32
29	NADPH oxidase signaling and cardiac myocyte function. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 47, 15-22.	0.9	119
30	Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. <i>Journal of Vascular Surgery</i> , 2009, 50, 1127-1134.	0.6	41
31	Involvement of NADPH Oxidases in Cardiac Remodelling and Heart Failure. <i>American Journal of Nephrology</i> , 2007, 27, 649-660.	1.4	80
32	NADPH oxidase and heart failure. <i>Current Opinion in Pharmacology</i> , 2006, 6, 148-153.	1.7	56
33	NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. <i>Cardiovascular Research</i> , 2006, 71, 208-215.	1.8	301
34	EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. <i>British Journal of Pharmacology</i> , 2004, 141, 580-585.	2.7	106